Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Unity Biotechnology, Inc is a biotechnology business based in the US. Unity Biotechnology shares (UBX) are listed on the NASDAQ and all prices are listed in US Dollars. Unity Biotechnology employs 63 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$4.75|
|52-week range||$2.72 - $15.44|
|50-day moving average||$4.27|
|200-day moving average||$5.58|
|Wall St. target price||$6.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.97|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||5.56%|
|3 months (2021-04-30)||-4.43%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
|Gross profit TTM||$-65,809,000|
|Return on assets TTM||-32.38%|
|Return on equity TTM||-88.04%|
|Market capitalisation||$209 million|
TTM: trailing 12 months
There are currently 3.0 million Unity Biotechnology shares held short by investors – that's known as Unity Biotechnology's "short interest". This figure is 11.7% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting Unity Biotechnology shares can be evaluated.
Unity Biotechnology's "short interest ratio" (SIR) is the quantity of Unity Biotechnology shares currently shorted divided by the average quantity of Unity Biotechnology shares traded daily (recently around 728363.30935252). Unity Biotechnology's SIR currently stands at 4.17. In other words for every 100,000 Unity Biotechnology shares traded daily on the market, roughly 4170 shares are currently held short.
However Unity Biotechnology's short interest can also be evaluated against the total number of Unity Biotechnology shares, or, against the total number of tradable Unity Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Unity Biotechnology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Unity Biotechnology shares in existence, roughly 60 shares are currently held short) or 0.0709% of the tradable shares (for every 100,000 tradable Unity Biotechnology shares, roughly 71 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Unity Biotechnology.
Find out more about how you can short Unity Biotechnology stock.
We're not expecting Unity Biotechnology to pay a dividend over the next 12 months.
Over the last 12 months, Unity Biotechnology's shares have ranged in value from as little as $2.72 up to $15.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Unity Biotechnology's is 0.2329. This would suggest that Unity Biotechnology's shares are less volatile than average (for this exchange).
Unity Biotechnology, Inc. , a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.